Welcome to our dedicated page for Zivo Bioscience - Warrants SEC filings (Ticker: ZIVOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zivo Bioscience - Warrants's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zivo Bioscience - Warrants's regulatory disclosures and financial reporting.
Zivo Bioscience, Inc. director and 10% owner reported buying additional company shares. On 11/28/2025, an indirect account, HEP Investments LLC, purchased 2,777 shares of Zivo Bioscience common stock at a price of $9 per share. After this transaction, the reporting person beneficially owned 577,872 shares of common stock indirectly through HEP Investments LLC.
Zivo Bioscience, Inc. director and 10% owner reported buying additional company shares. On 11/28/2025, an indirect account, HEP Investments LLC, purchased 2,777 shares of Zivo Bioscience common stock at a price of $9 per share. After this transaction, the reporting person beneficially owned 577,872 shares of common stock indirectly through HEP Investments LLC.
ZIVO Bioscience (ZIVO) filed its Q3 2025 10‑Q, showing modest revenue growth alongside tight liquidity and continued losses. Revenue was $65,625, up from $31,500, with gross margin of $21,288. The company reported a net loss of $1,033,056 for the quarter and operating cash outflow of $2,173,204 for the nine months.
Cash declined to $57,222 with total liabilities of $3,846,055 and a stockholders’ deficit of $(3,286,603). Shares outstanding were 3,832,327 as of September 30, 2025, and 3,888,595 as of November 9, 2025. Management states there is substantial doubt about the ability to continue as a going concern and estimates needing about $6.0 million over the next 12 months to fund basic operations.
During 2025, ZIVO raised funds via private equity and debt, including a $250,000 convertible note at 10% with warrants to purchase 1,793 shares at $13.94. Subsequent to quarter‑end (October 2025), the company sold 54,168 shares and 3,091 warrants, raising $390,000 in cash and exchanging $284,433 of related party payables. Material weaknesses in internal control over financial reporting persist.
ZIVO Bioscience (ZIVO) filed its Q3 2025 10‑Q, showing modest revenue growth alongside tight liquidity and continued losses. Revenue was $65,625, up from $31,500, with gross margin of $21,288. The company reported a net loss of $1,033,056 for the quarter and operating cash outflow of $2,173,204 for the nine months.
Cash declined to $57,222 with total liabilities of $3,846,055 and a stockholders’ deficit of $(3,286,603). Shares outstanding were 3,832,327 as of September 30, 2025, and 3,888,595 as of November 9, 2025. Management states there is substantial doubt about the ability to continue as a going concern and estimates needing about $6.0 million over the next 12 months to fund basic operations.
During 2025, ZIVO raised funds via private equity and debt, including a $250,000 convertible note at 10% with warrants to purchase 1,793 shares at $13.94. Subsequent to quarter‑end (October 2025), the company sold 54,168 shares and 3,091 warrants, raising $390,000 in cash and exchanging $284,433 of related party payables. Material weaknesses in internal control over financial reporting persist.